Alkermes plc – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryPharmaceuticals and Healthcare
Key Findings
Pharmaceuticals and Healthcare
Pharmaceuticals and Healthcare
Reasons To Buys
MarketLine
Key Highlights
Ireland
Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the treatment of schizophrenia and for the treatment of schizoaffective disorder; AMPYRA/FAMPYRA, which is a treatment to improve walking in adults with multiple sclerosis; and BYDUREON is for the treatment of type 2 diabetes. Co.'s product candidate include Aripiprazole Lauroxil Two-Month Dose for the treatment of schizophrenia, among others.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.